{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:57Z","timestamp":1779951777550,"version":"3.53.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032767","name":"Sichuan Medical Association","doi-asserted-by":"publisher","award":["2025RF27"],"award-info":[{"award-number":["2025RF27"]}],"id":[{"id":"10.13039\/100032767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study systematically evaluated the safety profile of esketamine for treatment-resistant depression through a meta-analysis, focusing on dose-dependent adverse events and associated risk factors to inform precision dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, the Mainland China Biomedical Literature Database (CBM), the China National Knowledge Infrastructure (CNKI) and Wanfang databases were searched from inception to March 2025. Randomized controlled trials evaluating esketamine for treatment-resistant depression were included. Primary outcomes included the incidence of adverse events, discontinuation due to adverse events, and clinical response or remission. Statistical analysis was conducted using RevMan 5.4.1, with subgroup analyses by dosage, administration route, and geographic region (Mainland China vs. International multi-regional).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine randomized controlled trials involving 1,449 patients were included. Dosages ranged from 28 to 84\u00a0mg for nasal spray and 0.20\u20130.40\u00a0mg\/kg for intravenous injection. Esketamine significantly increased the risk of nine adverse events, including nausea, dissociation, dizziness, vertigo, elevated blood pressure, and somnolence, compared with controls (P &amp;lt; 0.05). Risks were strongly dose-dependent: the high-dose group (\u226556\u00a0mg or 0.40\u00a0mg\/kg) showed a greater risk than the low-dose group (\u226428\u00a0mg or 0.20\u00a0mg\/kg), with RR for nausea of 3.72 versus 1.69 and RR for dissociation of 10.65 versus 3.27. Patients in International multi-regional studies also had higher risks of nausea, somnolence, and headache than those in Mainland China studies. Although esketamine improved the clinical response rate (RR = 1.94), it increased treatment discontinuation due to adverse events by 2.22-fold (P = 0.025).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Esketamine improves symptoms in patients with treatment-resistant depression but significantly increases dose-dependent adverse events. Clinical use should adopt personalized dosing strategies that balance efficacy and tolerability based on individual patient profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=1024830<\/jats:ext-link>\n                      , identifier CRD420251024830.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1792570","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:19:14Z","timestamp":1779949154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-dependent adverse events of esketamine in treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Yang","family":"Qu","sequence":"first","affiliation":[{"name":"West China Hospital Sichuan University Jintang Hospital, Jintang First People\u2019s Hospital, Anesthesia and Surgery Center","place":["Jintang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujin","family":"Li","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University Jintang Hospital, Jintang First People\u2019s Hospital, Anesthesia and Surgery Center","place":["Jintang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tian","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University Jintang Hospital, Jintang First People\u2019s Hospital, Anesthesia and Surgery Center","place":["Jintang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Tian","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University Jintang Hospital, Jintang First People\u2019s Hospital, Anesthesia and Surgery Center","place":["Jintang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Wu","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University Jintang Hospital, Jintang First People\u2019s Hospital, Anesthesia and Surgery Center","place":["Jintang, Sichuan, China"]},{"name":"West China Hospital Sichuan University Out-Patient Department","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1192\/j.eurpsy.2025.14","article-title":"Sleep-administered ketamine\/psychedelics: a streamlined strategy to address two challenges in research on ketamine and psychedelics","volume":"68","author":"Arjmand","year":"2025","journal-title":"Eur. Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"105410","DOI":"10.1016\/j.neubiorev.2023.105410","article-title":"Storm on predictive brain: a neurocomputational account of ketamine antidepressant effect","volume":"154","author":"Bottemanne","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/NDT.S391096","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/YIC.0000000000000527","article-title":"Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report","volume":"40","author":"Chevalier","year":"2025","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14737175.2019.1659728","article-title":"Esketamine nasal spray for treatment-resistant depression: a review of clinical evidence","volume":"19","author":"Citrome","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"110603","DOI":"10.1016\/j.pnpbp.2022.110603","article-title":"Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression","volume":"119","author":"Cook","year":"2022","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD011612","DOI":"10.1002\/14651858.CD011612.pub3","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"9","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ph16010031","article-title":"Impact of repeated doses of subcutaneous esketamine on acute dissociative symptoms in treatment-resistant depression","volume":"16","author":"Del Sant","year":"2022","journal-title":"Pharm. (Basel)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother. Psychosom."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1681060","DOI":"10.3389\/fphar.2025.1681060","article-title":"Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis","volume":"16","author":"Guo","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B15","volume-title":"Efficacy and Safety of Repeated Intravenous Esketamine Administration in Treatment-Resistant Depression: A Clinical Study [master's Thesis, Anhui Medical University]","author":"Han","year":"2022"},{"key":"B16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21r14086","DOI":"10.4088\/JCP.21r14086","article-title":"Rapidity of symptom improvement with intranasal esketamine for major depressive disorder: a systematic review and meta-analysis","volume":"84","author":"Hock","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10398562231211171","article-title":"What Clinicians need to know about intranasal esketamine for treatment-resistant depression?","volume":"31","author":"Hope","year":"2023","journal-title":"Australas. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1192\/bjp.2020.89","article-title":"Are we repeating mistakes of the past? A review of the evidence for esketamine","volume":"219","author":"Horowitz","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (aspire II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14740338.2022.2058488","article-title":"The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis","volume":"21","author":"Jawad","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00406-023-01732-5","article-title":"The correlation of esketamine with specific adverse events: a deep dive into the FAERS database","volume":"275","author":"Jiang","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaac.2025.02.015","article-title":"Effect of esketamine on depressive symptoms in adolescents with major depressive disorder at imminent suicide risk: a randomized psychoactive-controlled study","volume":"65","author":"Kosik-Gonzalez","year":"2026","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"177604","DOI":"10.1016\/j.ejphar.2025.177604","article-title":"The antidepressant potential of (2R,6R)-hydroxynorketamine: a detailed review of pre-clinical findings","volume":"999","author":"Koutrouli","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.2147\/NDT.S388764","article-title":"Efficacy and safety of esketamine combined with antidepressants for treatment-resistant depression: a meta-analysis","volume":"18","author":"Liu","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0269881120978398","article-title":"Repeated subcutaneous esketamine for treatment-resistant depression: impact of the degree of treatment resistance and anxiety comorbidity","volume":"35","author":"Lucchese","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international multi-regional expert opinion on the available evidence and implementation","volume":"178","author":"Mcintyre","year":"2021","journal-title":"Am. J. Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41398-024-03180-8","article-title":"Personalized use of ketamine and esketamine for treatment-resistant depression","volume":"14","author":"Medeiros","year":"2024","journal-title":"Transl. Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102127","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalmedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jpsychires.2024.11.010","article-title":"Intranasal esketamine for patients with major depressive disorder: a systematic review and meta-analysis","volume":"180","author":"Oraee","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e41495","DOI":"10.1097\/MD.0000000000041495","article-title":"Efficacy of esketamine nasal spray for treatment-resistant depression: a meta-analysis of randomized controlled studies","volume":"104","author":"Ouyang","year":"2025","journal-title":"Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40262-020-00953-4","article-title":"Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression","volume":"60","author":"Perez-Ruixo","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"B37","first-page":"9","article-title":"N-methyl-D-aspartate (NMDA) and non-NMDA binding sites in developing human frontal cortex","volume":"12","author":"Piggott","year":"1993","journal-title":"Neurosci. Res. Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1325399","DOI":"10.3389\/fpsyt.2024.1325399","article-title":"Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis","volume":"15","author":"Rodolico","year":"2024","journal-title":"Front. Psychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/10398562221093870","article-title":"Intranasal esketamine for depression: not so special K","volume":"30","author":"Rosenman","year":"2022","journal-title":"Australas. Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1037\/0021-843X.117.2.300","article-title":"The cultural shaping of depression: somatic symptoms in China, psychological symptoms in North America?","volume":"117","author":"Ryder","year":"2008","journal-title":"J. Abnorm. Psychol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/02791072.2024.2424283","article-title":"Esketamine-induced dissociation: a case report","volume":"58","author":"Scarcella","year":"2024","journal-title":"J. Psychoactive Drugs."},{"key":"B44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jad.2024.03.137","article-title":"Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-analysis","volume":"356","author":"Seshadri","year":"2024","journal-title":"J. Affect. Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry."},{"key":"B46","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/02698811221084055","article-title":"The antidepressant effect and safety of non-intranasal esketamine: a systematic review","volume":"36","author":"Smith-Apeldoorn","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1017\/S0033291723001058","article-title":"Reporting of harms in clinical trials of esketamine in depression: a systematic review","volume":"53","author":"Taillefer de Laportali\u00e8re","year":"2023","journal-title":"Psychol. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy to oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study","volume":"21","author":"Takahashi","year":"2021","journal-title":"BMC Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/ph18050627","article-title":"Auto-induction in oral esketamine treatment for treatment-resistant depression: an exploratory study","volume":"18","author":"Veraart","year":"2025","journal-title":"Pharm. (Basel)."},{"key":"B50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11126-020-09871-x","article-title":"Adverse effects of esketamine for the treatment of major depression disorder: findings from randomized controlled trials","volume":"93","author":"Yang","year":"2022","journal-title":"Psychiatr. Q."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","article-title":"Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study","volume":"48","author":"Zaki","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"B52","volume-title":"Efficacy and Safety of Esketamine Combined with ECT in Treatment-Resistant Depression: A Randomized Double-Blind Controlled Trial","author":"Zeng","year":"2022"},{"key":"B53","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jaac.2023.05.031","article-title":"Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial","volume":"63","author":"Zhou","year":"2024","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.12788\/jfp.0176","article-title":"Is ketamine effective and safe for treatment-resistant depression?","volume":"70","author":"Zorn","year":"2021","journal-title":"J. Fam. Pract."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1792570\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:19:19Z","timestamp":1779949159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1792570\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":54,"alternative-id":["10.3389\/fphar.2026.1792570"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1792570","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1792570"}}